A randomized, parallel controlled, double-blind, single-center phase I trial of recombinant variant COVID-19 vaccine (Sf9 cell)(WSK-V102) in people aged 18 years or older who have been immunized with COVID-19 vaccine for 3 months or more, or who have been infected with COVID-19 for 3 months or more

开始日期2023-03-11

申办/合作机构-

NCT05710289 / WithdrawnN/A

A Prospective Blood Collection Study to Assess the Immunogenicity of Homologous Booster Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization Among Adults of 18 Years and Older.

The purpose of this study is to assess the immunogenicity of nationally available pre-defined homologous booster vaccination of a SARS-CoV-2 WHO EUA qualified vaccination in adults aged 18 years and older

开始日期2023-02-01

申办/合作机构

SK bioscience Co., Ltd.

[+1]

100 项与 COVID-19 Vaccine(Janssen) 相关的临床结果

登录后查看更多信息

100 项与 COVID-19 Vaccine(Janssen) 相关的转化医学

登录后查看更多信息

100 项与 COVID-19 Vaccine(Janssen) 相关的专利（医药）

登录后查看更多信息

11,863

项与 COVID-19 Vaccine(Janssen) 相关的文献（医药）

2025-12-01·JOURNAL OF CLINICAL IMMUNOLOGY

Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome

Article

作者: Pasmans, Suzanne G M A ; Geers, Daryl ; Zaeck, Luca M ; Dalm, Virgil A S H ; de Vries, Rory D. ; Schappin, Renske ; GeurtsvanKessel, Corine H. ; Zaeck, Luca M. ; Dik, Willem A. ; Dik, Willem A ; Pasmans, Suzanne G. M. A. ; Bogers, Susanne ; Dalm, Virgil A. S. H. ; Gommers, Lennert ; Nouwen, Anouk E M ; GeurtsvanKessel, Corine H ; Nouwen, Anouk E. M. ; de Vries, Rory D

Abstract:

Background:

Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency.

Methods:

Vaccination responses in eight adult NS patients were assessed in a cross-sectional study performed between January and August 2022. Clinical patient data were retrospectively retrieved from electronic patient files. Immune responses to a polysaccharide Streptococcus pneumoniae vaccine (PPV23) and conjugate Haemophilus influenzae type b vaccine (ActHiB) were measured. SARS-CoV-2-specific (functional) antibody and T-cell responses following booster vaccination with an mRNA-based COVID-19 vaccine were compared to controls.

Results:

None of the included patients suffered from recurrent and/or severe infections that could be attributed to a B- and/or T-cell immunodeficiency. ActHiB induced immune responses were normal in 7/7 NS patients. PPV23 induced responses were absent in 1/7, diminished in 2/7, and normal in 4/7 patients. Levels of SARS-CoV-2-specific binding and neutralizing antibodies after mRNA-based COVID-19 booster vaccination in NS patients were comparable to controls. SARS-CoV-2-specific CD4 + T-cell responses were detectable in all NS patients. In contrast, SARS-CoV-2-specific CD8 + T-cell responses were detectable in only 2/6 NS patients. T-cell responses to a positive control antigen pool were comparable to controls.

Conclusions:

Vaccine-induced immune responses were detectable after polysaccharide, conjugate and mRNA-based vaccination in our cohort of NS patients. A spectrum of responsiveness to vaccine challenges was found, with the ranges of vaccine responses overlapping those demonstrated in healthy control populations.

2025-03-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

The development of therapeutics and vaccines against COVID-19.

Review

作者: Fei, Yingming ; Wang, Zhiwei ; Zhao, Tianyu ; Tong, Mingjiong

Since the COVID-19 pandemic, it has caused a great threat to the global economy and public health, initiatives have been launched to control the spread of the virus. To explore the efficacy of drugs, a large number of clinical trials have been carried out, with the purpose of providing guidelines based on high-quality evidence for clinicians. We mainly discuss therapeutic agents for COVID-19 and explain the mechanism, including antiviral agents, tocilizumab, Janus kinase (JAK) inhibitors, neutralizing antibody therapies and corticosteroids. In addition, the COVID-19 vaccine has been proven to be efficacious in preventing SARS-CoV-2 infection. We systematically analyzed four mainstream vaccine platforms: messenger RNA (mRNA) vaccines, viral vector vaccines, inactivated vaccines and protein subunit vaccines. We evaluated the therapeutic effects of drugs and vaccines through enumerating the most typical clinical trials. However, the emergence of novel variants has further complicated the interpretation of the available clinical data, especially vaccines and antibody therapies. In the post-epidemic era, therapeutic agents are still the first choice for controlling the progression of disease, whereas the protective effect of vaccines against different strains should be assessed comprehensively.

2025-03-01·Infectious Disease Modelling

Impact of vaccination on Omicron's escape variants: Insights from fine-scale modelling of waning immunity in Hong Kong

Article

作者: Zou, Yuling ; Ming, Wai-Kit ; Yuan, Hsiang-Yu ; Lo, Wing-Cheong

COVID-19 vaccine-induced protection declines over time. This waning of immunity has been described in modelling as a lower level of protection. This study incorporated fine-scale vaccine waning into modelling to predict the next surge of the Omicron variant of the SARS-CoV-2 virus. In Hong Kong, the Omicron subvariant BA.2 caused a significant epidemic wave between February and April 2022, which triggered high vaccination rates. About half a year later, a second outbreak, dominated by a combination of BA.2, BA.4 and BA.5 subvariants, began to spread. We developed mathematical equations to formulate continuous changes in vaccine boosting and waning based on empirical serological data. These equations were incorporated into a multi-strain discrete-time Susceptible-Exposed-Infectious-Removed model. The daily number of reported cases during the first Omicron outbreak, with daily vaccination rates, the population mobility index and daily average temperature, were used to train the model. The model successfully predicted the size and timing of the second surge and the variant replacement by BA.4/5. It estimated 655,893 cumulative reported cases from June 1, 2022 to 31 October 2022, which was only 2.69% fewer than the observed cumulative number of 674,008. The model projected that increased vaccine protection (by larger vaccine coverage or no vaccine waning) would reduce the size of the second surge of BA.2 infections substantially but would allow more subsequent BA.4/5 infections. Increased vaccine coverage or greater vaccine protection can reduce the infection rate during certain periods when the immune-escape variants co-circulate; however, new immune-escape variants spread more by out-competing the previous strain.

1,605

项与 COVID-19 Vaccine(Janssen) 相关的新闻（医药）

2024-12-11

·GlobeNewswire-Health Care

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infectionsTwo phase 1/2 clinical studies are ongoing to evaluate the safety profile and immune response induced by the combination vaccine candidates Paris, December 11, 2024. The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and older. Both candidates combine two already licensed and authorized vaccines with proven efficacy through randomized controlled studies, and with favorable tolerability. The first combination vaccine candidate (NCT06695117) consists of the influenza protein-based trivalent vaccine Fluzone High-Dose combined with the adjuvanted recombinant Novavax COVID-19 vaccine. The second candidate (NCT06695130) combines the influenza recombinant protein-based trivalent vaccine Flublok with the Novavax COVID-19 vaccine. Both Fluzone High-Dose and Flublok have been proven to prevent more influenza infections in older adults than standard-dose influenza vaccines in pivotal randomized clinical studies. Additionally, in real-world evidence studies they have demonstrated significant and consistent reductions in flu-related hospitalizations. The Novavax COVID-19 vaccine has been shown to have a better tolerability profile than currently available mRNA COVID-19 vaccines when administered as a booster dose. It has also demonstrated high efficacy against COVID-19 as primary vaccination in two pivotal phase 3 studies. Thomas TriompheExecutive Vice President, Vaccines, Sanofi“Building on our immunology expertise and on 12 years of robust clinical and real-world data, we aim to continue leading the way in protection against flu and its severe outcomes. Our goal is to develop a combined flu and COVID-19 vaccine that offers simpler scheduling and fewer injections without compromising on the industry leading levels of efficacy, safety and tolerability of the standalone vaccines included in our combination vaccine.” Fast Track designation was granted based on the potential for the combination vaccine candidates to address the significant individual and healthcare system burden of two serious illnesses that can result in hospitalization and death, particularly among older adults. Sanofi has initiated two separate phase 1/2 parallel, randomized, modified double-blind, multi-arm studies (NCT06695117 and NCT06695130) to evaluate the safety and immune response induced by the two combination vaccine candidates. About NCT06695117 and NCT06695130The two combination vaccine candidates consist of: NCT06695117: TIV-HD (FLUZONE High-Dose) combined with NVXC19 (Novavax COVID-19 vaccine) to prevent Influenza subtype A, influenza subtype B and coronavirus (SARS CoV-2) infections in individuals 50 years of age or older.NCT06695130: RIV3 (FLUBLOK) combined with NVXC19 (Novavax COVID-19 vaccine) to prevent Influenza subtype A, influenza subtype B and coronavirus (SARS CoV-2) infection in individuals 50 years of age or older. One recent systematic review and meta-analysis suggests a combination booster vaccine could increase the uptake of COVID-19 vaccines among the 50 years and above age group by 56%. Combination vaccines may also be attractive to healthcare professionals conducting immunization programs as they may be easier and quicker to administer with fewer injections to protect against multiple diseases, less errors and decreased syringe and vial disposal requirements. Influenza (flu) is a contagious, acute viral respiratory disease. Every year, there are an estimated 290,000 to 650,000 influenza-related respiratory deaths globally. In developed countries most deaths associated with flu occur in people aged 65 years or older. Adults aged 65 or older account for most hospitalizations from flu. Among this population there is a higher hospitalization rate for flu with 2-fold longer average length of hospital stay than with younger adults. One quarter of patients are readmitted to hospital within 90-days post-discharge. Flu can wreak havoc across major organ systems. It can lead to an 8-fold increased risk of stroke and pneumonia, a 10-fold increased risk of heart attack and among older adults hospitalized for flu, 1 in 5 experience a decline in their ability to independently undertake simple daily tasks, such as bathing, and dressing themselves. Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill resulting in hospitalization and death. Many individuals continue to experience long-term sequelae following COVID-19, also referred to as “long COVID”. Long COVID symptoms can vary from mild to severe, potentially necessitating extensive medical attention, and may even lead to disability. A meta-analysis of 12 studies shows that 30% of COVID-19 patients have persistent symptoms two years after infection, the most common of which are fatigue, cognitive problems, and pain. About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com Evan Berland | +1 215 432 0234 | evan.berland@sanofi.comNicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com Investor RelationsThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release

疫苗临床3期快速通道临床结果

2024-12-09

·Business Wire

First Subject Dosed in Initial Cohort of Phase 2b Clinical Study of CyanVac’s Intranasal COVID-19 Vaccine Candidate

ATHENS, Ga. & SAN JOSE, Calif.--( BUSINESS WIRE )--CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza virus 5 (PIV5)-based vector, announced today that the first participant has been dosed in a Phase 2b clinical study of CVXGA, its intranasal COVID-19 vaccine candidate. The study, supported by the U.S. Government’s (USG) Project NextGen , is designed to evaluate CVXGA against a U.S. Food and Drug Administration (FDA)-approved injectable mRNA-based COVID-19 vaccine, with both CVXGA and the comparator mRNA-based vaccine targeting the omicron variant KP.2 strain of SARS-CoV-2. Approximately 400 participants initially will be enrolled in sentinel and safety lead-in cohorts. Once an independent Data and Safety Monitoring Board (DSMB) reviews the safety data of the participants, and the Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the Department of Health and Human Services (HHS) provides approval, enrollment of approximately 9,600 additional participants for the second part of the trial will proceed. “This phase 2b trial represents a major milestone for our proprietary PIV5-based vaccine platform,” said Biao He, Ph.D., founder and CEO of CyanVac. “Recently we reported positive results from an earlier Phase 2a trial of CVXGA involving 227 adult volunteers. We expect this new Phase 2b trial to play a key role in confirming these results and validating the potential of our PIV5-based vaccine platform.” The Phase 2b study is being conducted through BARDA’s Clinical Studies Network and is expected to enroll approximately 10,000 adults representative of the U.S. population including people at high risk for severe COVID-19. Participants will be followed for evidence of SARS-CoV-2 infection for 12 months after vaccination. The study is designed to assess the relative efficacy of CVXGA versus mRNA vaccine in the prevention of symptomatic COVID-19. The study also will evaluate CVXGA’s ability to prevent asymptomatic infections, which could be an indicator of the vaccine's ability to prevent the transmission or spread of this respiratory pathogen. This project is being funded with federal funds from HHS, ASPR, BARDA, under Other Transaction (OT) number 75A50123D00005. About CVXGA CVXGA is a clinical-stage COVID-19 vaccine candidate based on a proprietary parainfluenza virus 5 (PIV5) vector that encodes the spike (S) protein of SARS-CoV-2. The PIV5 vector was developed at the University of Georgia and is based on a respiratory virus that is not known to cause disease in humans which has been commonly administered to dogs as part of combination distemper/kennel cough vaccines for decades. CyanVac and its affiliate, Blue Lake Biotechnology, are developing CVXGA as a single-dose, intranasal vaccine to prevent SARS-CoV-2 infection and serious complications associated with COVID-19. Preclinical studies have demonstrated that CVXGA is immunogenic and protective and prevents transmission of SARS-CoV-2. Phase 1 and Phase 2a clinical studies have shown that subjects dosed with CVXGA showed robust mucosal, cellular and humoral immune responses with limited or no reactogenicity and no serious events assessed as related to the vaccine. About CyanVac and Blue Lake Biotechnology CyanVac LLC and its affiliate, Blue Lake Biotechnology, Inc., are developing intranasal vaccines that harness the full breadth of the immune system to keep people healthy, prevent serious infectious diseases, and protect the health of vulnerable populations. Our platform uses a proprietary parainfluenza virus 5 vector into which a foreign gene from a targeted pathogen is inserted. We have generated a robust clinical-stage pipeline of best-in-class vaccines designed to overcome the limitations of existing vaccine technologies. Our lead product candidates have demonstrated potential for high efficacy and durability with few vaccine-related side effects. Learn more at CyanVac and Blue Lake Biotechnology .

疫苗临床2期临床结果

2024-12-04

·PRNewswire

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million GAITHERSBURG, Md., Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million. The agreement includes a transfer of assets, including a 150,000-square foot state-of-the-art recombinant protein manufacturing facility with support buildings, along with the existing workforce and all related and required infrastructure. The agreement provides Novavax with significant, non-dilutive capital, further enabling the Company to advance its corporate growth strategy to drive value from its early- and late-stage pipeline using its proven technology platform, consisting of Matrix-M adjuvant and nanoparticle protein-based technology. In addition to the $190 million cash payment in 2024 and additional $10 million in 2025, Novavax expects the sale of the facility to result in annual operating cost reductions of approximately $80 million. "The decision to sell the Czech Republic manufacturing facility aligns with our previously announced commitment to evolve Novavax into a more lean and agile organization focused on partnering our pipeline assets and technology platform," said John C. Jacobs, President and Chief Executive Officer, Novavax. "We are thankful to our dedicated colleagues in the Czech Republic who have contributed to Novavax's mission of delivering our technology to address unmet needs. We look forward to working with Novo Nordisk to ensure a successful transition." Following closure of the agreement, expected by December 30, 2024, full responsibility for the manufacturing facility will be transferred to Novo Nordisk. About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M™ malaria vaccine. Please visit novavax.com and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the proposed sale of Novavax's Czech Republic manufacturing site, the expected timing of completion of the proposed sale, the receipt of the consideration to be received for the proposed sale, the anticipated operating cost reductions and Novavax's corporate growth strategy, value drivers and priorities are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inability of the parties to complete the proposed sale, including due to the failure to satisfy the condition precedent to the closing of the sale; the risk that the proposed sale disrupts Novavax's plans and operations; the inability to recognize the anticipated operating cost reductions and other anticipated benefits of the proposed sale; unanticipated costs related to the proposed sale challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in conducting clinical trials; challenges in implementing its global restructuring and cost reduction plan; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, challenges related to the seasonality of vaccinations against COVID-19; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and , for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Luis Sanay, CFA 240-268-2022 [email protected] Media Giovanna Chandler 240-720-7804 [email protected] SOURCE Novavax, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗信使RNA

100 项与 COVID-19 Vaccine(Janssen) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07B	DB15857

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒感染	美国	Janssen Pharmaceuticals, Inc.	2021-02-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流感病毒感染	临床3期	美国	Janssen Vaccines & Prevention BV	2021-11-02
流感病毒感染	临床3期	比利时	Janssen Vaccines & Prevention BV	2021-11-02
流感病毒感染	临床3期	波兰	Janssen Vaccines & Prevention BV	2021-11-02
严重急性呼吸综合征	临床3期	南非	Janssen Vaccines & Prevention BV	2021-02-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04765384 (HORIZON 1, CTgov)	临床2期	新型冠状病毒感染	51	messenger Ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine+COVID-19 mRNA vaccine (Group 1 (Adults): Ad26.COV2.S 5*10^10 vp)	淵醖廠獵齋鬱選願繭製(衊製選衊衊鏇襯壓憲鏇) = 範鏇觸積蓋衊齋遞鹹觸鬱鬱鑰齋觸製夢網醖網 (膚顧鏇窪襯襯遞鹽獵夢, 觸夢糧繭蓋鹹構遞憲製 ~ 糧鬱鏇鹹憲願獵壓鬱憲) 更多	-	2024-11-13
				Ad26.COV2.S (Groups 2 and 3 (Adults): Ad26.COV2.S 5*10^10 vp)	淵醖廠獵齋鬱選願繭製(衊製選衊衊鏇襯壓憲鏇) = 醖蓋築範衊壓獵膚窪觸鬱鬱鑰齋觸製夢網醖網 (膚顧鏇窪襯襯遞鹽獵夢, 築艱憲繭淵糧淵醖憲鑰 ~ 願鏇衊築製製窪廠鬱憲) 更多
NCT04614948 (ENSEMBLE2 \| ENSEMBLE 2, CTgov)	临床3期	新型冠状病毒感染	31,835	adenovirus type 26 vector coronavirus-2 spike protein (Ad26.COV2.S) (Double Blind Phase: Ad26.COV2.S)	鑰齋顧選遞餘鹹襯淵衊(願製範壓蓋鏇鹹鹽衊廠) = 壓選衊糧窪蓋壓壓鏇鹹築鹹糧鑰艱淵製鬱積糧 (觸窪窪鬱壓襯鬱選襯繭, 廠衊齋構壓鹽範衊範築 ~ 艱構衊艱製繭鹽鏇衊鹹) 更多	-	2024-10-09
				placebo+Ad26.COV2.S (Double Blind Phase: Placebo)	鑰齋顧選遞餘鹹襯淵衊(願製範壓蓋鏇鹹鹽衊廠) = 蓋獵製壓願選選餘觸鹹築鹹糧鑰艱淵製鬱積糧 (觸窪窪鬱壓襯鬱選襯繭, 網窪鑰鏇壓遞糧鏇積夢 ~ 艱鑰壓觸夢積淵獵顧顧) 更多
Pubmed \| BMC Infect Dis	N/A	新型冠状病毒感染	-	COVID-19 vaccine (Specific Populations)	齋獵範鑰壓鹹艱遞鬱醖(鹽鏇憲選襯醖壓憲廠製) = 壓遞膚衊齋蓋淵願餘繭選遞觸憲顧醖壓淵顧簾 (蓋膚夢鹽觸衊壓範願窪, 5.0 ~ 7.9)	-	2024-09-27
				COVID-19 vaccine (Control Group)	齋獵範鑰壓鹹艱遞鬱醖(鹽鏇憲選襯醖壓憲廠製) = 觸顧鹽壓鏇繭窪齋鹹範選遞觸憲顧醖壓淵顧簾 (蓋膚夢鹽觸衊壓範願窪, 8.3 ~ 11.9)
NCT04908722 (CTgov)	临床3期	新型冠状病毒感染	1,609	Ad26.COV2.S (Group 1: Ad26.COV2.S 9x10^10 vp)	獵窪選簾繭選餘糧範獵(憲廠蓋製醖淵獵壓鑰鑰) = 鹽膚衊遞蓋遞壓齋鹽鏇網壓夢鹹築襯構艱獵壓 (鑰鹹願壓觸鏇鏇鑰網構, 壓醖築範願簾齋願淵繭 ~ 遞鹽醖遞壓醖遞窪膚繭) 更多	-	2024-05-23
				Ad26.COV2.S (Group 2: Ad26.COV2.S 7x10^10 vp)	獵窪選簾繭選餘糧範獵(憲廠蓋製醖淵獵壓鑰鑰) = 鬱製糧艱網製獵製衊願網壓夢鹹築襯構艱獵壓 (鑰鹹願壓觸鏇鏇鑰網構, 壓鬱製觸觸淵淵齋範鏇 ~ 廠顧築餘夢願齋憲願簾) 更多
NCT05007080 (HORIZON 2, CTgov)	临床2期	新型冠状病毒感染	304	Placebo (Group 1: Ad26.COV2.S 2.5*10^10 vp + Placebo)	鏇願製遞膚襯網鑰選鏇(醖願簾選鏇鏇醖衊鏇鹽) = 築襯鏇蓋積鑰鹽構繭壓醖繭廠網觸窪蓋襯願築 (願醖鏇鹽蓋鹽願鏇壓鏇, 夢膚鏇夢餘繭鑰獵壓網 ~ 膚壓膚製艱齋製繭網範) 更多	-	2024-05-23
				Placebo (Group 2: Ad26.COV2.S 1.25*10^10 vp + Placebo)	鏇願製遞膚襯網鑰選鏇(醖願簾選鏇鏇醖衊鏇鹽) = 襯範鏇觸願壓鹽築鑰窪醖繭廠網觸窪蓋襯願築 (願醖鏇鹽蓋鹽願鏇壓鏇, 鹹窪網衊網遞糧夢淵齋 ~ 網鏇衊襯獵醖衊繭製窪) 更多
EHA2024	N/A	慢性淋巴细胞白血病	-	COVID-19 vaccine (Individuals diagnosed with CLL before the study start)	遞繭鑰醖醖觸獵廠窪憲(鹽鏇繭夢鏇醖蓋廠築襯) = 鹹憲遞顧選網顧襯蓋構餘積範淵餘壓襯淵製餘 (觸窪製遞餘膚餘餘夢窪 ) 更多	-	2024-05-14
AASLD2023	N/A	肝病	211	COVID-19 vaccine	襯壓獵衊積齋築鏇蓋範(壓鹽鬱窪繭窪廠獵選鏇) = worsened after vaccination but hadn't clinical significance 積遞夢鏇觸網襯蓋範觸 (製鹹醖蓋顧醖鏇艱觸鏇 ) 更多	-	2023-11-10
				COVID-19 vaccine
NCT05091307 (CTgov)	临床3期	新型冠状病毒感染 \| 流感病毒感染	861	Placebo+Ad26.COV2.S (Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo)	選顧衊膚壓壓艱鬱簾鑰(鑰襯積憲網遞選糧積壓) = 齋鬱觸壓鬱獵製壓製廠顧構憲選遞鏇鹹襯選鬱 (獵顧膚顧齋網網餘鬱願, 鹹衊築醖簾築襯簾襯簾 ~ 餘壓壓繭遞鑰網遞鑰齋) 更多	-	2023-08-08
				Placebo+Ad26.COV2.S (Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S)	選顧衊膚壓壓艱鬱簾鑰(鑰襯積憲網遞選糧積壓) = 築襯鹽醖鏇鹹積築顧衊顧構憲選遞鏇鹹襯選鬱 (獵顧膚顧齋網網餘鬱願, 壓遞範艱鬱憲醖願餘廠 ~ 窪衊鬱艱獵繭積餘鑰壓) 更多
NCT05047640 (CTgov)	临床3期	新型冠状病毒感染	58	BNT162b2 vaccine (BNT162b2 Vaccine Group)	壓構鑰餘窪襯夢廠製獵(廠顧選簾簾鑰範壓鑰獵) = 網築壓繭鹹齋壓艱壓鏇衊膚餘襯選範淵遞簾願 (鏇膚遞膚壓鏇廠膚鬱餘, 膚獵築壓憲壓願鏇鏇鹹 ~ 糧遞願繭壓簾淵夢構憲) 更多	-	2023-06-22
				JNJ-78436735 Vaccine (JNJ-78436735 Vaccine Group)	壓構鑰餘窪襯夢廠製獵(廠顧選簾簾鑰範壓鑰獵) = 網蓋艱構鹽願鹹鏇壓鹹衊膚餘襯選範淵遞簾願 (鏇膚遞膚壓鏇廠膚鬱餘, 選餘遞齋艱繭鏇憲鹽選 ~ 壓憲遞網糧鏇製糧觸顧) 更多
COVAD (EULAR2023)	N/A	自身免疫性疾病	9,201	COVID-19 VACCINE (Pregnant with AID*)	齋憲鏇齋窪醖齋鑰淵膚(齋襯艱夢糧窪積餘憲膚) = Overall AE, minor AE, and major AE were reported significantly more frequently by pregnant than non-pregnant patients (45% vs. 26%, p=0.01; 40% vs. 25.9%, p=0.03; 17.5% vs. 4.6%, p<0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC. 鬱齋夢選製夢鹹積願積 (壓獵繭淵製製遞鬱簾糧 ) 更多	-	2023-05-31
				COVID-19 VACCINE (Breastfeeding with AID*)